Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Small Molecule Therapeutics

Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2–Expressing Neuroblastoma Preclinical Models

Thinh H. Nguyen, Balakrishna Koneru, Sung-Jen Wei, Wan Hsi Chen, Monish Ram Makena, Eduardo Urias, Min H. Kang and C. Patrick Reynolds
Thinh H. Nguyen
1Cancer Center, Departments of Pediatrics, Cell Biology & Biochemistry, and Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
2Department of Pharmacology and Neuroscience, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Balakrishna Koneru
1Cancer Center, Departments of Pediatrics, Cell Biology & Biochemistry, and Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sung-Jen Wei
1Cancer Center, Departments of Pediatrics, Cell Biology & Biochemistry, and Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wan Hsi Chen
1Cancer Center, Departments of Pediatrics, Cell Biology & Biochemistry, and Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wan Hsi Chen
Monish Ram Makena
1Cancer Center, Departments of Pediatrics, Cell Biology & Biochemistry, and Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Monish Ram Makena
Eduardo Urias
1Cancer Center, Departments of Pediatrics, Cell Biology & Biochemistry, and Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min H. Kang
1Cancer Center, Departments of Pediatrics, Cell Biology & Biochemistry, and Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
2Department of Pharmacology and Neuroscience, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Patrick Reynolds
1Cancer Center, Departments of Pediatrics, Cell Biology & Biochemistry, and Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
2Department of Pharmacology and Neuroscience, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for C. Patrick Reynolds
  • For correspondence: patrick.reynolds@ttuhsc.edu
DOI: 10.1158/1535-7163.MCT-19-0385 Published December 2019
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: September 2019 to January 2021

AbstractFull-text HTMLPDF
Total2351332480

Cited By

Article Information

Volume 18, Issue 12, pp. 2270-2282

DOI 
https://doi.org/10.1158/1535-7163.MCT-19-0385
PubMed 
31484706

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • Received April 12, 2019
  • Revision received July 25, 2019
  • Accepted August 27, 2019
  • Published first September 4, 2019.

Article Versions

  • Previous version (September 4, 2019 - 09:00).
  • Previous version (September 5, 2019 - 07:13).
  • Previous version (September 26, 2019 - 07:05).
  • Previous version (November 21, 2019 - 06:57).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2019 American Association for Cancer Research.

Author Information

  1. Thinh H. Nguyen1,2,
  2. Balakrishna Koneru1,
  3. Sung-Jen Wei1,
  4. Wan Hsi Chen1,
  5. Monish Ram Makena1,
  6. Eduardo Urias1,
  7. Min H. Kang1,2, and
  8. C. Patrick Reynolds1,2,*
  1. 1Cancer Center, Departments of Pediatrics, Cell Biology & Biochemistry, and Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
  2. 2Department of Pharmacology and Neuroscience, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.
  1. ↵*Corresponding Author:
    C. Patrick Reynolds, Texas Tech University Health Sciences Center School of Medicine, 3601 4th Street, STOP 9445, Lubbock, TX 79430-9445. E-mail: patrick.reynolds{at}ttuhsc.edu
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 18 (12)
December 2019
Volume 18, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2–Expressing Neuroblastoma Preclinical Models
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2–Expressing Neuroblastoma Preclinical Models
Thinh H. Nguyen, Balakrishna Koneru, Sung-Jen Wei, Wan Hsi Chen, Monish Ram Makena, Eduardo Urias, Min H. Kang and C. Patrick Reynolds
Mol Cancer Ther December 1 2019 (18) (12) 2270-2282; DOI: 10.1158/1535-7163.MCT-19-0385

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2–Expressing Neuroblastoma Preclinical Models
Thinh H. Nguyen, Balakrishna Koneru, Sung-Jen Wei, Wan Hsi Chen, Monish Ram Makena, Eduardo Urias, Min H. Kang and C. Patrick Reynolds
Mol Cancer Ther December 1 2019 (18) (12) 2270-2282; DOI: 10.1158/1535-7163.MCT-19-0385
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Discovery of a Novel Anticancer Therapeutic
  • eFT226, a Selective Inhibitor of eIF4A-Mediated Translation
  • Peptide Inhibiting Breast Cancer by Disrupting SND1–MTDH
Show more Small Molecule Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement